Protocol Ledger

NCT03559270 · Phase III · TERMINATED

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Interventional Phase III clinical trial protocol NCT03559270 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-27 Enrollment: 374 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03559270
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)374 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03559270
Protocol FieldVerified Registry Value
NCT IdentifierNCT03559270
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment374 participants (ACTUAL)
Registered Start Date2018-06-27
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI